I
nfection from chronic hepatitis C virus (HCV) is a significant cause of cirrhosis, hepatocellular carcinoma (HCC), and liver-related death worldwide, with an estimated 140 to 170 million persons infected. 1 In the United States, an estimated 2% to 3% of persons born between 1945 and 1965 have chronic hepatitis C, with 2 to 3 million persons infected. 2 Because of the paucity of large population-based prospective cohort studies of persons with chronic hepatitis C, the factors associated with progression of disease such as viral genotype, viral load, mode of acquisition of infection, and previous exposure to hepatitis B virus to mention a few, are not well elucidated. Since 1995, the Alaska Native Tribal Health Consortium Liver Disease and Hepatitis Program (LDHP), in collaboration with the Arctic Investigations Program and the Division of Viral Hepatitis of the Centers for Disease Control and Prevention, have been conducting a population-based cohort study Alaska Hepatitis C Study ([AK-HEPC]) of liver-related adverse outcomes of chronic HCV infection in American Indian/Alaska Native persons residing in Alaska. We previously determined that the AK-HEPC cohort had similar risk factors for acquisition and HCV genotype distribution when compared with the National Health and Nutritional Examination Survey conducted in 1994 of infected persons from the general US population.
3,4 Previously, we analyzed outcome both prospectively and retrospectively through 2006 in this cohort and compared outcome with persons who recovered from HCV who were recruited at the same time. We found that end-stage liver disease (ESLD) was associated with older age and alcohol use. We also found that compared with HCV genotype 2, genotype 3 infection was associated with a higher risk of ESLD on multivariate analysis, but not compared with genotype 1. 5 For this analysis, we included all persons recruited from 1995 to 2012 and only included data obtained prospectively starting from the time of consent. We examined 11 risk factors for any association with ESLD, HCC, and liver-related death. Herein, we present the results of this study.
Methods
The Alaska Native Tribal Health Consortium coordinates Alaska Tribal Health System health care throughout the state of Alaska. Further details of the population and health care delivery system have been described previously and in the Supplementary Tables 1  and 2. 4 Electronic health records are used in these statewide Tribal facilities. Testing for anti-HCV was conducted at the laboratory at the Alaska Native Medical Center (ANMC); all positive results were reflexed automatically for HCV RNA testing and then downloaded into our HCV computerized registry. All patients in the HCV registry, whether they were participants in the study or not, were mailed a letter every 6 months reminding them to go to their local clinic to undergo liver function tests. A list of patients in their area with chronic HCV are sent to each regional facility and updated twice yearly. Testing for anti-HCV is conducted at the laboratory at ANMC and all positive results are reflexed automatically for HCV RNA testing and then downloaded into the HCV registry. The HCV registry includes extensive laboratory data, clinical data, and demographic data, and is used primarily for management of infected persons. All pertinent laboratory tests performed at ANMC on patients in the HCV registry are downloaded automatically into the AK-HEPC database twice weekly. Laboratory data performed at the regional hospitals and clinics are added to the database at the time of field clinic visits and by access given to our program to these facilities' electronic health records systems. The LDHP works with Tribal providers throughout Alaska and conducts field hepatology clinics at all regional hospitals once or twice a year. We use telemedicine, Vidyo clinics (Hackensack, NJ), teleradiography, and other means to care for HCV-infected patients. Since the beginning of this study, all patients who are eligible have been offered Food and Drug Administration-approved drugs for treatment at the time based on guidelines from the American Association for the Study of Liver Diseases/Infectious Disease Society of America. 6 During the period when interferonbased therapies were the only licensed regimens available, more than 50% of patients were deemed eligible candidates for treatment, but most refused. 7 However, in the era of direct-acting antiviral agents licensed in the United States since the fall of 2014, almost all eligible patients now agree to therapy and currently are offered direct-acting antivirals regardless of liver fibrosis stage. All patients in the registry who were both anti-HCV positive and HCV RNA positive for at least 1 year have been invited to join the AK-HEPC study. The study was approved by the Alaska Area and Centers for Disease Control and Prevention Investigational Review Boards. The study also was approved by all regional Tribal health organization boards in Alaska. All participants provided written informed consent.
At the time of AK-HEPC study enrollment, study nurses conducted an extensive interview of each participant to obtain information on risk factors and demographic data that were reviewed in our previous publication. 5 Information was obtained directly from the HCV registry, by chart review including International Classification of Diseases, 9th revision (ICD-9) liverrelated diagnosis, and review of the State of Alaska Death Tapes from 1995 through 2012. In addition, an extensive chart review was performed on each participant at the end of the study period to examine for clinical evidence of liver disease that occurred during the study period. We defined advanced fibrosis as either a Knodell fibrosis score of 3 or higher, equivalent to Metavir fibrosis of F3/F4, on liver biopsy, or Aspartate amino transferase platlet ratio index (APRI) of 1.5 or higher, which has a specificity of approximately 90%. 8 ESLD was defined by the presence of 1 or more of the following: ascites, esophageal varices, hepatic encephalopathy, or coagulopathy (international normalized ratio 1.2 or platelet count <130,000 on at least 2 occasions >2 months apart). The diagnosis of HCC was made by pathologic confirmation or on radiographic imaging examination (computed tomography, ultrasound, or magnetic resonance imaging) consistent with a mass lesion with typical features for HCC including enhancing during the arterial phase. Liver-related death was defined as death with immediate cause from a complication of liver disease or death, with liver disease listed as a contributing cause in medical chart review and death certificate and also included persons who underwent a liver transplant. We evaluated the cohort for 11 different potential contributing factors that might be associated with each of the 4 adverse outcomes. These included age at start of enrollment, sex, residence (urban or rural), risk factor for acquisition of HCV (blood transfusion before 1992, injecting drug use, or other), HCV genotypes 1, 2, and 3, presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg), heavy alcohol consumption (defined as >50 g average/d at enrollment), tobacco smoker, obesity as defined by a BMI greater than 30, type II diabetes, and HCV RNA level. HCV RNA level was divided into the following 5 categories: less than 50,000; 50,000 to less than 200,000; 200,000 to less than 1 million; 1 million to less than 5 million; and more than 5 million IU/mL. Because of the few persons in the AK-HEPC cohort with active hepatitis B or human immunodeficiency virus (HIV) infection, persons with these co-infections were excluded from analysis.
Laboratory Testing
Detection of anti-HCV antibodies (EIA2.0; Abbott Laboratories, Chicago, IL) and HCV RNA (COBAS TaqMan HCV Test, v2.0; Roche Molecular Diagnostics, Basal, Switzerland) were performed at the Alaska Native Medical Center laboratory (Anchorage, Alaska). HCV viral genotype was determined by real-time polymerase chain reaction by Quest Diagnostics (Hepatitis C Genotype, LIPA).
Statistical Analysis
The starting point for all survival analyses was the date of the confirmatory HCV testing. Age was calculated at the start of clinical follow-up evaluation and divided into the following quartiles (<30, 30-39, 40-49, and 50 years). For risk factors we divided the cohort into persons with a pre-1993 blood transfusion, persons with a history of intravenous drug use, and all others. Persons living in Anchorage, Juneau, Fairbanks, and surrounding areas were considered urban residents, with all others classified as rural. For persons treated for HCV, the end of follow-up evaluation was defined as the treatment start date. The end of follow-up evaluation among those with an outcome was the date of detection of ESLD, HCC, liver-related death (primary outcomes), or advanced fibrosis (secondary outcome). Among those without an outcome, the date of their last clinical follow-up evaluation or their date of death was used. For ESLD, the date of their first ESLD objective finding was used. We used the Cox-proportional hazards model to report univariable and multivariable P values. We used a purposeful forward selection method to build a final multivariable model. Factors with a univariable P value less than .25 were considered in the building of the multivariable models. Variables were considered confounders and remained in the model if their exclusion changed the value of the coefficients of interest by more than 15%. All reported P values are 2-sided, were not adjusted for multiple testing, and a value less than .05 was considered statistically significant. Kaplan-Meier survival estimates were used to report the probabilities of the outcome after 15 years of follow-up evaluation.
Results
Among 1132 persons found to have chronic HCV through 2012, 1080 (95.4%) were enrolled. Table 1 provides the demographic, risk factors, clinical, social, and laboratory characteristics of this cohort. Two thirds of participants (66%) were infected with HCV genotype 1, 90% were infected with HCV genotype 1a, and 19% and 14% were infected with HCV genotypes 2 and 3, respectively. At study entry, 22% of genotype 3 patients had an increased APRI score (1.5), which did not differ from 21% and 23% in genotype 1 and 2 patients, respectively. The 1080 persons were followed up prospectively for 11,171 person years (mean, 10.3 y). The median age at the time of enrollment was 41 years, and 51% of participants were female. HIV co-infection was found in 29 and HBsAg was found in 10; as mentioned in the Methods section, these patients were not included in the outcome analysis. A total of 157 patients received interferon-based antiviral treatment, of whom 76 achieved sustained virologic response and were censored from further analysis after that time. More than half of the patients were tobacco smokers and 10% had diabetes. Daily heavy alcohol intake was reported by 14% of participants. More than half of the patients lived in cities with a population greater than 10,000 (urban).
During the study period, 341 persons developed advanced fibrosis, 210 developed ESLD, 40 developed HCC, and 96 had a liver-related death, with some patients developing more than one of these adverse outcomes. Of the 341 patients with advanced fibrosis, 190 (56%) were identified by liver biopsy, and 151 (44%) were identified by their APRI scores. Of the 40 patients with HCC, 39 met the definition of HCC we used in the Methods section. One patient with a 4-cm lesion of the liver on ultrasound, liver failure, history of stroke, and multiple contractures could not fit comfortably into the computed tomography or magnetic resonance imaging scanners. He developed a second lesion several months later and died of liver failure. We included him as a probable case of HCC. Table 2 shows the results of hazard ratios (HRs) in univariate analysis for the 11 risk factors for all 3 primary outcomes. By using HCV genotype 1 as the referent, persons infected with genotype 3 were significantly more likely to develop ESLD and liver-related death and those with genotype 2 were less likely to develop ESLD. Developing ESLD was associated significantly with age at start of follow-up evaluation, HCV genotype 3, heavy alcohol use, and type II diabetes. HCC was associated with male sex and age at start of follow-up evaluation.
Liver-related death was associated with age, genotype 3, presence of anti-HBc, type II diabetes mellitus (DM2), and heavy alcohol use. Results for the secondary outcome of advanced fibrosis were very similar to the results for ESLD and are included in Supplementary  Tables 1 and 2. The multivariable model for ESLD identified for HCV genotype (1, 2, and 3), age at cohort entry, heavy alcohol use (average, >50 g/d), obesity (BMI 30), and DM2 (Table 3) as factors associated significantly with risk of ESLD. The model for HCC identified HCV genotype, age at cohort entry, and sex as risk factors. HCV genotype, age at cohort entry, and heavy alcohol use were significant factors associated with liver-related death. Persons infected with HCV genotype 3 were significantly more likely to develop all 3 adverse outcomes, ESLD, HCC, and liver-related death, than those infected with HCV genotype 1. After 15 years of clinical follow-up evaluation, the probability of developing ESLD for those infected with HCV genotype 3 was 48%, and for liver-related death was 24%. Older age at enrollment also was associated with all 3 adverse outcomes. The increases in risk for developing ESLD were heavy alcohol use (adjusted HR [aHR], 2.2; 95% CI, 1.6-3.2), obesity (aHR, 1.4; 95% CI, 1.0-1.9; P ¼ .03), and DM2 (aHR, 1.5; 95% CI, 1.0-2.3; P ¼ .03). The risk for developing HCC was higher for males than females (aHR, 3.6; 95% CI, 1.6-8.2). Persons with heavy alcohol use were at increased risk for liverrelated death (aHR, 2.9; 95% CI, 1.8-4.6) ( Table 3) . Several important risk factors were not associated with any of the adverse outcomes on multivariable analysis. Surprisingly, HCV RNA level had no effect on any of the outcomes. The risk factor for acquisition also did not have any effect, and neither did the presence of anti-HBc in the absence of HBsAg, which could indicate occult hepatitis B virus (HBV).
Discussion
The AK-HEPC study was a large and long populationbased cohort study to examine the long-term outcome of chronic HCV infection. This population-based study of more than 1000 participants (94% of the known Alaska Native persons with chronic HCV infection in the state), followed up for 11,171 person-years, a mean of more than 10 years, was designed to examine prospectively the adverse events resulting from HCV infection. The study encompassed a large amount of clinical and laboratory data coupled with baseline risk factor, electronic medical records, State of Alaska death records, and other data collected at entry plus personal clinical statewide follow-up evaluation by the providers and nurses on our LDHP team. We found an important association with the adverse outcomes of ESLD, HCC, and liver related death in those infected with HCV genotype 3 compared with genotype 1. In the AK-HEPC cohort, 14% had genotype 3. In this cohort, within 15 years of diagnosis, two thirds of those with genotype 3 had progressed to advanced fibrosis, half to ESLD, one quarter had died or had received a liver transplant, and almost 1 in 10 developed HCC. Recently, a retrospective Veterans' Affairs (VA) study, using a search of their HCV Clinical Registry and ICD-9 codes, found that HCV genotype 3 was associated with a 31% higher risk of developing cirrhosis and an 80% higher risk of developing HCC compared with genotype 1 patients. 9 The VA study showed that HCV genotype 3 had a higher risk of cirrhosis and HCC than genotype 1. We confirmed their findings of an increased risk of HCC and ESLD and extended this significant risk to include advanced fibrosis and liver-related death. In their discussion, the investigators commented on the limitation of their study because it was retrospective in nature and that a large prospective cohort study with sufficient follow-up evaluation was unlikely to be conducted because of cost and feasibility. However, we actually conducted such a study as reported herein. The VA study relied on ICD-9 codes whereas we actively followed up participants prospectively. One third of the patients in the VA Clinical Registry did not have HCV genotype testing performed, as opposed to only 4 of 1080 persons in our study, and the VA study did not eliminate persons with HIV or HBV co-infection, plus included patients who previously were treated for HCV. Genotype 3 may excerpt some of its adverse effects by increasing liver steatosis independent of diabetes or obesity, resulting in more rapid liver fibrosis, which then leads to higher rates of cirrhosis and HCC. 10 In a previous study looking at factors associated with the amount of fibrosis on liver biopsy, we found that steatosis was prominent in those with genotype 3 and an independent risk factor. Fibrosis and steatosis were more advanced in genotype 3 patients compared with genotypes 1 and 2 when adjustment for BMI and diabetes was performed. 11 As seen in Table 2 , there were no differences in adverse outcomes between urban and rural areas or differences in the distribution of the important risk factors of HCV genotype, obesity, risk exposure, or alcohol use. Surprisingly, we found that HCV RNA level was not associated with any of the outcomes in multivariable analysis. In performing this analyses, we divided participants into 5 groups based on their initial HCV RNA level, ranging from less than 50,000 to more than 5 million IU/ mL, with well over 100 participants in each group. This was in contrast to what has been found in studies of chronic HBV infection, our long-term prospective chronic hepatitis B outcome study in AN/AI persons, in whom higher levels of HBV DNA, especially greater than 20,000 IU/mL, are a significant risk factor in developing HCC and cirrhosis. [12] [13] [14] It is not clear why viral level in HCV was not found to be associated with outcome. It is possible that the vigorous immune response evoked by the presence of HCV, regardless of viral level, is the critical factor in promoting progression, rather than the activity of the virus itself. We also found that HCVinfected persons with occult HBV infection, those negative for HBsAg but positive for anti-HBc, had no greater risk of developing any of the adverse outcomes.
There were a few limitations to our study. First, all participants were American Indian/Alaska Native persons, however, because the characteristics in the AK-HEPC cohort did not differ from those found in the National Health and Nutritional Examination Survey study of the general US population with regards to prevalence, distribution of risk factors, and prevalence of HCV genotypes, 4 it is less likely that significant differences in risk factors for disease outcome are present. In addition, response to interferon-based therapy were similar to previous US studies and registration trials. 15 In conclusion, our study has yielded some important findings regarding the risk factors for progression of HCV to adverse life-threatening outcomes. The most striking finding was that HCV genotype 3 has significant risk for the development of all adverse outcomes studied, suggesting that persons with genotype 3 HCV infection should be prioritized for treatment. However, currently genotype 3 is the most difficult HCV genotype to treat, especially for patients with cirrhosis or who were treated previously and failed to achieve sustained virologic response. Fortunately, new pangenotype oral antivirals are on the horizon and could be available soon, offering the opportunity to better target patients with HCV genotype 3.
